DAX+0,72 % EUR/USD-0,47 % Gold0,00 % Öl (Brent)0,00 %

Geron Announces Appointment of New Executive to Focus on Corporate Strategy

Nachrichtenquelle: Business Wire (engl.)
03.12.2019, 14:00  |  113   |   |   

Geron Corporation (Nasdaq: GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. With this appointment, all functions of a fully-integrated, late-stage drug development executive leadership team are now in place.

“We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external alliances rounds out our executive team’s capabilities,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “More importantly, he will provide a commercial lens to Geron’s corporate strategy that will be instrumental as we evaluate current and future indications of imetelstat to maximize the value of the program, as well as other potential assets to diversify the Company’s pipeline over the long-term.”

In his role at Geron, Mr. Kapur will be a member of the Company’s Executive Management Committee. His initial focus will be on developing value-creating strategic plans to build Geron’s hematology-oncology franchise while leading the Company’s assessment of additional indications for imetelstat. As Geron continues to advance the imetelstat program toward potential commercialization over time, he will be responsible for implementing Geron’s commercial strategy and forming a commercial organization.

“I am excited to be joining Geron,” said Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer. “Having seen imetelstat’s transformative potential for disease modification through telomerase inhibition while at Janssen, I strongly believe that imetelstat has great promise in hematology-oncology, and look forward to helping strategically build imetelstat and Geron into an important and meaningful enterprise for clinicians, patients, shareholders and employees.”

Mr. Kapur brings more than 19 years of U.S. and global biopharmaceutical experience to Geron. Most recently, he was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., where he created a strategic commercialization roadmap to help the company transition from clinical stage to a commercial entity. Prior to that, Mr. Kapur was Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb Company. In this role, he led early-asset and biomarker commercial groups with a mandate for accelerating the development of the immuno-oncology portfolio comprising over 20 pipeline assets, including collaborations. Previously, Mr. Kapur was Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, where he was responsible for growing the newly created Baxalta Oncology Division into a top-tier global oncology business and leading the global commercialization efforts of the company’s oncology portfolio. During Mr. Kapur’s 15-year tenure at Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), he held marketing and sales leadership roles of increasing responsibility for both the U.S. and ex-U.S. markets. As Vice President, Commercial Leader, Hematology Franchise in Janssen’s Global Commercial Strategy Organization, he led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets, including myeloid malignancies. During this time at Janssen, Mr. Kapur worked on early commercialization plans for imetelstat. Among Mr. Kapur’s most recognized achievements while at Janssen were the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex.

Seite 1 von 3
Geron (Delaware) Aktie jetzt für 4€ handeln - auf Smartbroker.de



Diesen Artikel teilen
Wertpapier

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
Franc


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Aus der Community
LUS Wikifolio-Index Performance von Kryptowährungen Index Zertifikat Open-End (LASW)
Chart: arniarni

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
14.01.20